Does the scope of the investigation include the Express stent, the basis of Taxus?
That has been mentioned, but the focus has been on what happened in ’98. That’s where the time has been spent. But it has come up. Q: Is there a threat to the Express that would affect Taxus? A: The Express is ours. It doesn’t matter what anybody else says or thinks. It’s ours. We developed it from scratch, and the risk there is just the random risk that always is there if there’s something going on in court. That’s a fact. Q: What’s your second act? A: There’s a list of things. There aren’t going to be any more multibillion-dollar opportunities like Taxus is. But there are lots of $500 million opportunities. There are initiatives in women’s health, abnormal uterine bleeding, endoscopy. And so on and so on. There’s a list of a dozen of these things. There are a lot of opportunities, not all in cardio area. Some in the endosurgery area as well — the one-third of our business that just keeps trucking along and people don’t think about because it’s fragmented.
